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The history of the diagnostics and therapy (management) of
atherosclerosis and, in close connection with it, dyslipidemia,
has reached an important stage. In the 1950s, we used the word
hypercholesterinemia, but later on we began using the correct
term: dyslipidemia. Today, it is clear that the process of
atherosclerosis, which leads to cardiovascular diseases, is initi-
ated or augmented not only by quantitative changes of the
molecules taking part in the lipid metabolism, but also by their
qualitative or functional changes. Dysfunctional high-density
lipoprotein cholesterol (HDL-C), small, dense low-density
lipoprotein cholesterol (LDL-C), and the various enzyme
defects are only a couple of examples supporting this statement.
With the concept of pre-diabetes serving as a model, in the
everyday prevention way of thinking, the term impaired lipid
metabolism may be preferable.
The question of the priority of LDL-C and non-HDL-C is
fundamental in a different way of thinking. In their paper,
Ramjee et al. (1) carefully and thoroughly investigated the
significance of non–HDL-C and also the question of apolipo-
protein B. We agree with the final conclusion, that non–
HDL-C should be taken more into consideration as a risk
factor and as a therapeutic target. It should be applied much
more extensively in daily medical practice, especially in light of
the worldwide spread of obesity, hypertension, diabetes melli-
tus, and metabolic syndrome.
What makes a good risk marker? It is easily measured and
calculated with a low-cost procedure, not to increase healthcare
Contradictions Between AC and LDL-C Calculated by Friedewald FormulaTable 1 Contradictions Between A and LDL-C Calculated by Friedewal
TC AC LDL-C(1) LDL-
250 220 200 19
210 190 18
200 180 17
240 210 190 18
200 180 17
190 170 16
200 170 150 14
160 140 13
150 130 12
190 160 140 13
150 130 12
140 120 11
160 130 110 10
120 100 9
110 90 8
130 100 80 7
90 70 6
80 60 5Each value is measured in mg/dl. LDL-C(1): if TG  100 mg/dl; LDL-C(2): if TG  150 mg/dl; LDL-C(3): i
AC  atherogenic cholesterol; HDL  high-density lipoprotein; LDL  low-density lipoprotein; TC  totexpenses. Non–HDL-C is ideal in almost every aspect, except for its
name. Our opinion is that the term atherogenic cholesterol (AC)
illustrates its significance more effectively and can be kept in mind
much more easily than non–HDL-C. Everything that is not HDL-C
is atherogenic; therefore, non–HDL-C  AC. In everyday usage, it
ay be helpful to speak about good cholesterol (i.e., HDL-C, to date
xclusively), bad cholesterol (i.e., LDL-C), and besides these, AC.
To shed some light on the question, we prepared a table that
emonstrates the contradictions between AC and LDL-C
alculated by the Friedewald formula (Table 1). The table
shows the distortions caused by fasting triglycerides within the
normal (400 mg/dl) triglyceride level. We would like to raise
attention to the significance of different HDL-C levels mea-
sured beside matching triglyceride levels. It is clearly shown that
there can be a 40 to 60 mg/dl difference in the LDL-C levels at
a certain AC (non–HDL-C) value, according to the actual
metabolic state. The table shows that, regarding high cardio-
vascular risk patients, the true risk is more reliably represented
by a 150 to 160 mg/dl AC (non–HDL-C) value than by taking
only the LDL-C value into account.
In daily medical practice, it is strongly recommended that
AC values be taken into consideration in addition to determin-
ing total cholesterol and HDL-C levels. If the values minimally
required to determine the AC value are not measured in a
fasting state (postprandial state), then we may be able to catch
a glimpse of the cardiometabolic risk decades in advance.
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0f TG  200 mg/dl; and LDL-C(4): if TG  300 mg/dl.
al cholesterol; TG  triglycerides.
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Reply
We thank Dr. Reiber and colleagues for their thoughtful
comments regarding non–high-density lipoprotein cholesterol
(non–HDL-C). Many believe that the latest portends “state of
the art” by virtue of being the most recent development. It is
important not to equate the latest with the best. What is truly
state of the art is to begin to look “beyond low-density
lipoprotein cholesterol” (LDL-C), and we believe at this time
that non–HDL-C is the best choice of the two.
Similar to apoB, non–HDL-C is largely influenced by
LDL-C and accounts for the cholesterol in all atherogenic
lipoproteins, thus enabling superior performance to LDL-C
(1). Negligible net reclassification indices with apoB compared
to conventional lipid ratio reference models in prospective
epidemiologic studies underscore the questionable practical
utility of apoB at this time (2,3). More important are the
findings of slightly better performance of non–HDL-C com-
pared to apoB in direct pair-wise analyses from prospective
on-treatment data in recent large randomized, placebo-
controlled trials (4).
The reality is that both non–HDL-C and apoB outperform
DL-C (5). However, available evidence does not clearly point to
uperiority of either biomarker to the other in CV risk stratification.
Non–HDL-C currently proves to be a better marker for imple-
entation given comparable performance as apoB with the added
enefit of practicality, simplicity, and cost. Without question, more
ata from clinical trials and population databases are needed, and high
riority needs to be given to direct evaluation of both markers in
andomized controlled trials. We agree with Dr. Reiber and col-
eagues that the term “non-HDL,” although simple mathematically,
an be confusing. Atherogenic cholesterol (AC) or atherogenic lipid
raction may be more suitable titles than non–HDL-C.
We maintain that non–HDL-C is state of the art, and remains
he best choice marker at this time.
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Skeletal Muscle Disease
as Noncardiac Cause of
Cardiac Troponin T Elevation
We have read the recent article by Jaffe et al. (1) concerning the
specificity of cardiac troponins in chronic skeletal muscle disorders
with great interest. The authors reported increased concentrations
of creatine kinase isoenzyme creatine kinase-myocardial band
(CK-MB) and cardiac troponin T (cTnT) without concomitant
increases in cardiac troponin I (cTnI) in patients with skeletal
myopathies, including body myositis, in whom no clinical evidence
of myocardial ischemia was observed. Western blot analyses of
tissue biopsy specimens from these patients revealed the presence
of protein bands of molecular weight similar to that of cTnT.
Accordingly, the possibility of re-expression of cTnT in regener-
ating skeletal muscle has been raised and discussed. In this context,
we (2) have observed re-elevations of both CK-MB and cTnT but
not of cTnI in a patient with rhabdomyolysis and initial cardiac
involvement.
A 27-year-old man with a history of amphetamine abuse devel-
oped severe rhabdomyolysis after an intestinal operation due to
intestinal herniation with bowel gangrene. The activity of creatine
kinase showed a maximum level of 459,400 U/l on the fifth postop-
erative day, with CK-MB index of 0.04%, indicative of severe skeletal
muscle damage. He initially had biochemical evidence of myocardial
cell damage, with a mild but significant increase in cTnT (third-
generation assay, Roche Diagnostics, Basel, Switzerland) and cTnI
(Ortho Clinical Diagnostics, Raritan, New Jersey) levels, determined
on the 3rd postoperative day. Thereafter, levels of all the cardiac
biomarkers measured showed a gradual decline toward the corre-
sponding reference ranges. However, both CK-MB mass and cTnT
concentrations began to rise again 9 days after the operation, reaching
the maximum levels of 14-fold and 8-fold the upper reference limit of
CK-MB (5.0 ng/ml) and cTnT (0.10 ng/ml) on the 18th postoper-
ative day, respectively. During this postoperative period, no increase in
cTnI concentration was observed.
In the past decade, the hypothesis of re-expression of cTnT in
regenerating skeletal muscle was advanced by several published
reports that showed increases in circulating cTnT but not cTnI
levels in patients with chronic skeletal muscle and renal diseases (1). It
